Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

被引：0
|
作者：
P. G. Corrie
W. Qian
B. Basu
J. W. Valle
S. Falk
C. lwuji
H. Wasan
D. Palmer
M. Scott-Brown
J. Wadsley
S. Arif
J. Bridgewater
D. Propper
R. Gillmore
A. Gopinathan
R. Skells
P. Bundi
R. Brais
K. Dalchau
L. Bax
A. Chhabra
A. Machin
A. Dayim
K. McAdam
S. Cummins
L. Wall
R. Ellis
A. Anthoney
J. Evans
Y. T. Ma
C. Isherwood
A. Neesse
D. Tuveson
D. I. Jodrell
机构：
[1] Cambridge University Hospitals NHS Foundation Trust (Addenbrooke’s Hospital),Gastroenterology and Gastrointestinal Cancer Clinic
[2] Cancer Research UK—Cambridge Institute,undefined
[3] University of Cambridge,undefined
[4] University of Manchester and The Christie NHS Foundation Trust,undefined
[5] Bristol Haematology and Oncology Centre,undefined
[6] Leicester Royal Infirmary,undefined
[7] Hammersmith Hospital,undefined
[8] Imperial College,undefined
[9] Clatterbridge Cancer Centre,undefined
[10] University Hospital Coventry and Warwickshire,undefined
[11] Weston Park Hospital,undefined
[12] Velindre Cancer Centre,undefined
[13] UCL Cancer Institute,undefined
[14] Barts Cancer Institute,undefined
[15] The Royal Free Hospital,undefined
[16] Peterborough City Hospital,undefined
[17] Royal Surrey County Hospital,undefined
[18] Western General Hospital,undefined
[19] Royal Cornwall Hospitals,undefined
[20] St. James’s University Hospitals,undefined
[21] Beatson West of Scotland Cancer Centre,undefined
[22] University of Glasgow,undefined
[23] Queen Elizabeth Hospital,undefined
[24] University of Göttingen,undefined
[25] Cold Spring Harbor Laboratory,undefined
来源：
British Journal of Cancer | 2020年 / 122卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1760 / 1768
页数：8
相关论文
共 50 条
  • [41] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
  • [42] The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
    Zhang, Feng
    Wang, Yuyang
    Yang, Fangfang
    Zhang, Yuming
    Jiang, Man
    Zhang, Xiaochun
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 535 - 546
  • [43] Eligibility of metastatic pancreatic adenocarcinoma (MPA) patients for first-line palliative intent nab-paclitaxel plus gemcitabine (NG) versus FOLFIRINOX (FIO)
    Peixoto, Renata D'Alpino
    Renouf, Daniel John
    Lim, Howard John
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [44] Efficacy of SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma
    Singhal, Nimit
    Sigal, Darren
    Tebbutt, Niall C.
    Hezel, Aram F.
    Nagrial, Adnan
    Lumba, Sumit
    George, Thomas J.
    Smith, Sheri Lynn
    Gagnon, Suzanne
    Cullen, Michael T.
    Walker, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [45] Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
    Jin, Gang
    Guo, Shiwei
    Zhang, Yanqiao
    Ma, Yue
    Guo, Xiaodong
    Zhou, Xiaocui
    Yu, Qin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [47] Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment
    Pretta, Andrea
    Ziranu, Pina
    Giampieri, Riccardo
    Donisi, Clelia
    Cimbro, Erika
    Spanu, Dario
    Lai, Eleonora
    Pecci, Federica
    Balconi, Francesca
    Lupi, Alessio
    Pozzari, Marta
    Persano, Mara
    Murgia, Sara
    Pusceddu, Valeria
    Puzzoni, Marco
    Berardi, Rossana
    Scartozzi, Mario
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (05) : 655 - 660
  • [48] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Zong, Yuan
    Yuan, Jiajia
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1529 - 1536
  • [49] A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).
    Corrie, Philippa
    Qian, Wendi
    Basu, Bristi
    Valle, Juan W.
    Falk, Stephen
    Iwuji, Chinenyu
    Wasan, Harpreet Singh
    Palmer, Daniel H.
    Scott-Brown, Martin
    Wadsley, Jonathan
    Arif, Seema Safia
    Bridgewater, John A.
    Propper, David
    Gillmore, Roopinder
    Gopinathan, Aarthi
    Bax, Lisa
    Machin, Andrea
    Neesse, Albrecht
    Tuveson, David A.
    Jodrell, Duncan Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
    Ursula M. Vogl
    Haleh Andalibi
    Alexander Klaus
    Laurenz Vormittag
    Wolfgang Schima
    Bettina Heinrich
    Alice Kafka
    Thomas Winkler
    Leopold Öhler
    BMC Cancer, 19
12345